Concert Pharma (CNCE) Initiates Placebo-Controlled Phase 2 of CTP-656 in CF in U.S.; Plans Open-Label Phase 2 in EU in Q2
Tweet Send to a Friend
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) provided further details on the development plan in the U.S. and Europe for CTP-656, a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
